Synthesis, in vitro antiviral evaluation, and stability studies of bis(s-acyl-2-thioethyl) ester derivatives of 9-[2- (phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability

Journal of Medicinal Chemistry

Volumn 39, Issue 25, 1996, Pages 4958-4965

  Benzaria, Samira ^a,c   Pélicano, Hélène ^a   Johnson, Richard ^a   Maury, Georges ^a   Imbach, Jean Louis ^a   Aubertin, Anne Marie ^b   Obert, Georges ^b   Gosselin, Gilles ^a  

^a CNRS   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE DERIVATIVE; 9 [2 [O,O' BIS(PIVALOYLOXY)METHYL]PHOSPHONOMETHOXY]ETHYL]ADENINE; 9 [2 [O,O' BIS(PIVALOYLTHIO)ETHYL]PHOSPHONOMETHOXY]ETHYL]ADENINE; ADEFOVIR; CARBOXYLESTERASE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; EMBRYO; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; STOMACH JUICE;

ADENINE; ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE; DRUG STABILITY; HERPESVIRUS 1, HUMAN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHONIC ACIDS; PRODRUGS; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT;

EID: 0029731207     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960289o     Document Type: Article

References (45)

1. For a review, see: Naesens, L.; Balzarini, J.; De Clercq, E. Therapeutic potential of PMEA as an antiviral drug. Med. Virol. 1994, 4, 147-159.
2. De Clercq, E. Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochem. Pharmacol. 1991, 42, 963-972.
3. Walker, R. E.; Vogel, S. E.; Jaffe, H. S.; Polis, M. A.; Kovacs, J. A.; Faloon, J.; Davey, R. T.; Ebeling, D.; Cundy, K.; Paar, D.; Markowitz, N.; Masur, H.; Lane, H. C. A phase I/II study of PMEA in HIV infected patients. Abstracts of Papers; 1st National Conference on Human Retroviruses and Related Infections, Washington, DC, 1993; Abstract 522.
4. Balzarini, J.; Naesens, L.; Slachmuylders, J.; Niphuis, H.; Rosenberg, I.; Holy, A.; Schellekens, H.; De Clercq, E. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS 1991, 5, 21-28.
5. Bronson, J. J.; Ghazzouli, I.; Hitchcock, M. J. M.; Russel, J. W.; Klunk, L. J.; Kern, E. R.; Martin, J. C. In vivo anti-retrovirus and anti-cytomegalovirus activity of 9-((2-phosphonylmethoxy)-ethyl)adenine (PMEA). Abstracts of Papers; 5th International Conference on AIDS, Montreal, Canada, 1989; Abstract M.C.P. 74.
6. Starrett, J. E., Jr.; Tortolani, D. R.; Russel, J.; Hitchock, M. J. M.; Whiterock, V.; Martin, J. C.; Mansuri, M. M. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). J. Med. Chem. 1994, 37, 1857-1864.
7. Alexander, P.; Holy, A. Prodrugs of analogs of nucleic acid components. Collect. Czech. Chem. Commun. 1994, 59, 2127-2165.
8. Périgaud, C.; Girardet, J.-L.; Gosselin, G.; Imbach, J.-L. Comments on nucleotide delivery forms. In Advances in antiviral drug design; De Clercq, E., Ed.; JAI Press Inc.: Greenwich, CT, 1996; Vol. 2, pp 147-172.
9. Jones, R. J.; Bischofberger, N. Minireview: nucleotides prodrugs. Antiviral Res. 1995, 27, 1-17.
10. Midoux, P.; Negre, E.; Roche, A. C.; Mayer, R.; Monsigny, M.; Balzarini, J.; De Clercq, E.; Mayer, E.; Ghaffar, A.; Gangemi, J. D. Drug targeting: anti-HSV-1 activity of mannosylated polymerbond 9-(2-phosphonylmethoxyethyl)adenine. Biochem. Biophys. Res. Commun. 1990, 167, 1044-1049.
11. Alexander, P.; Holy, A.; Masojidkova, M. Synthesis of 9-(2-phosphinomethoxyethyl)adenine and related compounds. Collect. Czech. Chem. Commun. 1994, 59, 1870-1878.
12. Alexander, P.; Holy, A.; Masojidkova, M. Preparation of 9-(2-phosphonomethoxyethyl)adenine esters as potential prodrugs. Collect. Czech. Chem. Commun. 1994, 59, 1853-1869.
13. Glazier, A. Potent topical anti-herpes activity of a lipophilic phosphorus prodrug for the antiviral agent PMEA. Antiviral Res. 1995, 26, A306.
14. Glazier, A.; Buckheit, R.; Yanachkova, M.; Yanachkov, I.; Wright, G. E. Lipophilic phosphorus prodrugs for the antiviral agent PMEA. Antiviral Res. 1994, 23 (Suppl. 1), 65.
15. Starrett, J. E., Jr.; Tortolani, D. R.; Hitchock, M. J. M.; Martin, J. C.; Mansuri, M. M. Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl)9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res. 1992, 19, 267-273.
16. Puech, F.; Gosselin, G.; Lefebvre, I.; Pompon, A.; Aubertin, A. M.; Kirn, A.; Imbach, J.-L. Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process. Antiviral Res. 1993, 22, 155-174.
17. Srinivas, R. V.; Robbins, B. L.; Connely, M. C.; Gong, Y. F.; Bischofberger, N.; Fridland, A. Pivaloyloxymethyl esters of acyclic nucleoside phosphonates. Int. Antiviral News 1994, 2, 53-55.
18. Naesens, L.; Neyts, J.; Balzarini, J.; Bischofberger, N.; De Clercq, E. Antiviral efficacy in mice of oral bis(POM)-PMEA, the bis-(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res. 1995, 26, A276.
19. Naesens, L.; Neyts, J.; Balzarini, J.; Bischofberger, N.; De Clercq, E. Pharmacokinetics in mice of bis(POM)-PMEA, the bis-(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res. 1995, 26, A277.
20. Naesens, L.; Neyts, J.; Balzarini, J.; Bischofberger, N.; De Clercq, E. In vivo antiretroviral efficacy of oral bis(POM)-PMEA, the bis(pivaloyloxymethyl)prodrug of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA). Nucleosides Nucleotides 1995, 14, 767-770.
21. Naesens, L.; Balzarini, J.; Bischofberger, N.; De Clercq, E. Antiretroviral activity and pharmacokinetics in mice of oral bis-(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 1996, 40, 22-34.
22. Srinivas, R. V.; Robbins, B. L.; Connely, M. C.; Gong, Y. F.; Bischofberger, N.; Fridland, A. Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl)prodrugs of acyclic nucleoside phosphonates. Antimicrob. Agents Chemother. 1993, 37, 2247-2250.
23. Cundy, K. C.; Fishback, J. A.; Shaw, J.-P.; Lee, M. L.; Socke, K. F.; Yisor, G.C.; Lee, W. A. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm. Res. 1994, 11, 839-843.
24. GS840, a PMEA prodrug, enters trials for HIV-infection. Antiviral Agents Bull. 1994, 7, 232-233.
25. Barditch-Crovo, P. A.; Toole, J.; Burgee, H.; Wachsman, M.; Ebeling, D.; Cundy, K. C.; Jaffe, H. S.; Lietman, P. S. A randomized, double-blind, placebo-controlled phase I/II evaluation of 9-[-2-(bispivaloyloxy-methyl) phosphonylmethoxyethyl] adenine (bis-POM PMEA), an orally bioavailable prodrug of the anti-HIV nucleotide, PMEA. Antiviral Res. 1995, 26, A229.
26. Lefebvre, I.; Périgaud, C.; Pompon, A.; Aubertin, A.-M.; Girardet, J.-L.; Kirn, A.; Gosselin, G.; Imbach, J.-L. Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 1995, 38, 3941-3950.
27. Périgaud, C.; Gosselin, G.; Lefebvre, I.; Girardet, J. L.; Benzaria, S.; Barber, I.; Imbach, J. L. Rational design for cytosolic delivery of nucleoside monophosphates: "SATE" and "DTE" as enzymelabile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 1993, 3, 2521-2526.
28. Périgaud, C.; Aubertin, A. M.; Benzaria, S.; Pélicano, H.; Girardet, J.-L.; Maury, G.; Gosselin, G.; Kirn, A.; Imbach, J.-L. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine. Biochem. Pharmacol. 1994, 48, 11-14.
29. Benzaria, S.; Girardet, J.-L.; Périgaud, C.; Aubertin, A. M.; Pélicano, H.; Maury, G.; Gosselin, G.; Kirn, A.; Imbach, J.-L. The SATE pronucleotide derivative of ddA : a more potent HIV inhibitor than AZT. Nucleic Acids Symp. Ser. 1994, 31, 129-130.
30. Girardet, J.-L.; Périgaud, C.; Aubertin, A.-M.; Gosselin, G.; Kirn, A.; Imbach, J.-L. Increase of the anti-HIV activity of D4T in human T-cell culture by the use of the SATE pronucleotide approach. Bioorg. Med. Chem. Lett. 1995, 5, 2981-2984.
31. Holy, A.; Rosenberg, I. Synthesis of 9-[2-(phosphonylmethoxy)-ethyl]adenine and related compounds. Collect. Czech. Chem. Commun. 1987, 52, 2801-2809.
32. Bronson, J. J.; Ghazzouli, I.; Hitchcock, M. J. M.; Webb, R. R., II; Martin, J. C. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2(phosphonylmethoxy)propyl]cytosine. J. Med. Chem. 1989, 32, 1457-1463.
33. Bronson, J. J.; Kim, C. U.; Ghazzouli, I.; Hitchcock, M. J. M.; Kern, E. R.; Martin, J. C. Synthesis and antiviral activity of phosphonylmethoxyethyl derivatives of purine and pyrimidine bases. In Nucleotides analogues as antiviral agents; Martin, J. C., Ed.; American Chemical Society: Washington, DC; 1989; Vol. 401, pp 72-87.
34. Bailey, W. F.; Rivera, A. D. Acetolysis of cyclic acetals : regioselective acylative cleavage of cyclic formals. J. Org. Chem. 1984, 49, 4958-4964.
35. Foye, W. O.; Kauffman, J. M.; Kim, Y. H. Synthesis of 4-alkyl-4H-benzo[e]- and 4H-pyrido[2,3-e]-1,2,4-triazin-3-one 1-oxides for potential anticancer activity. J. Heterocycl. Chem. 1982, 19, 497-501.
36. Miyake, A.; Yamaoka, M. Method for producing 1-iodoalkyl acylates. Eur. Patent Appl. E.P. 143 601, June 5, 1985; Chem. Abstr. 1986, 104, 5589z.
37. Palu, G.; Stefanelli, S.; Rassu, M.; Parolin, C.; Balzarini, J.; De Clercq, E. Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Antiviral Res. 1991, 16, 115-119.
38. Blackburn, G. M.; Gait, M. J. Nucleic acids in chemistry and biology; IRL Press: Oxford, New York, Tokyo, 1990; pp 71-135.
39. Hanes, C. S.; Isherwood, F. A. Separation of the phosphoric esters on the filter paper chromatogram. Nature 1949, 154, 1107-1112.
40. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, G.; De Clercq, R. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
41. Moog, C.; Wick, A.; Le Bur, P.; Kirn, A.; Aubertin, A.-M. Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1. Antiviral Res. 1994, 24, 274-288.
42. 50, synergism, antagonism, low-dose risk, receptor binding and enzyme kinetics. Computer software for Apple II series and IBM-PC and instruction manual; Elsevier-Biosoft, Elsevier Science Publishers: Cambridge, U.K., 1985; pp 19-28.
43. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J. Immunol. Methods 1983, 65, 55-63.
44. De Clercq, R.; Holy, A.; Rosenberg, I.; Sakuma, T.; Balzarini, J.; Maudgal, P. L. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986, 323, 464-467.
45. De Clercq, E.; Descamps, J.; Verhelst, J.; Walker, R. T.; Jones, A. S.; Torrence, P. F.; Shugar, D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J. Infect. Dis. 1980, 141, 563-574.